LENSAR (NASDAQ:LNSR) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, highlighted by the continued commercial momentum of its ALLY Adaptive Cataract Treatment System.
The company reported full-year recurring revenue of $46.3 million, a 15% increase compared to 2024, with recurring streams now accounting for 79% of total annual revenue.
The expansion of LENSAR’s high-margin "razor-and-blade" model was driven by a 22% year-over-year increase in worldwide procedure volumes.
Central to this growth is the rapid placement of the ALLY system; the installed base for the flagship platform reached approximately 200 units by year-end, representing a 48% surge over the previous year.
Including legacy platforms, LENSAR’s total combined installed base grew to roughly 435 systems, with a current backlog of 13 units awaiting installation.
The fourth quarter specifically generated $16 million in total revenue.
While the company reported a net loss of $1.5 million for the quarter, its balance sheet was significantly bolstered by a strategic update regarding its relationship with Alcon.
During the period under review, LENSAR and Alcon executed a termination agreement for their previously proposed merger, under which LENSAR will retain a $10 million merger deposit.
Elsewhere, LENSAR ended the fiscal year with $18 million in cash and investments.
Management indicated that the company is well-capitalized to continue its market share gains, particularly as more surgeons transition from legacy laser technology to the integrated ALLY workstation.